Gainers & Losers Of The Day: GALT, CYNO, CARA, AVIR, OHRP...

(RTTNews) - The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of February 14, 2017.

GAINERS

1. Galectin Therapeutics Inc. (GALT)

Gained 40.63% to close Tuesday's (Feb.14, 2017) trading at $1.80.

News: The company made a presentation at BIO CEO & Investor Conference on February 13, 2017 at 3:00 p.m. Eastern time.

Near-term catalyst:

-- Top-line data from a phase IIb trial of GR-MD-02 in nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis are anticipated in December of this year. -- GR-MD-02 is also being explored in severe skin diseases like moderate-to-severe plaque psoriasis and severe atopic dermatitis. Galectin is scouting for a partner to advance the skin disease indications.

2. Cynosure Inc. (CYNO)

Gained 28.01% to close Tuesday's trading at $65.93.

News: Cynosure is to be acquired by Hologic Inc. (HOLX) for $66 per share in cash.

The per share purchase price corresponds to an equity value of approximately $1.65 billion and an enterprise value of $1.44 billion net of cash.

Cynosure has a broad portfolio of more than 20 products across major categories including non-invasive body contouring, hair removal, skin revitalization and women's health. The company reported revenues of $433.5 million in 2016.

3. ImmunoCellular Therapeutics Ltd. (IMUC)

Gained 22.31% to close Tuesday's trading at $2.96.

News: No news

Near-term catalyst: Preliminary data from phase I open-label trial of ICT-121 in recurrent glioblastoma expected around mid-2017.

4. XOMA Corp. (XOMA)

Gained 20.75% to close Tuesday's trading at $5.82. The stock has gained 44% in the last 2 trading days.

News: No news

Recent event: On Feb.13, 2017, the company agreed to sell 1.2 million shares of its common stock at a price of $4.03 each and 5,003 shares of convertible preferred stock directly to Biotechnology Value Fund, L.P. and certain of its affiliates ("BVF") in a registered direct offering.

The gross proceeds from the offering are expected to be approximately $25.0 million. The offering is expected to close on or about February 15, 2017.

5. Cellect Biotechnology Ltd. (APOP)

Gained 18.83% to close Tuesday's trading at $6.12.

News: Dual-listed Cellect to voluntarily file for delisting from Tel Aviv Stock Exchange.

Cellect is traded on both the NASDAQ and Tel Aviv Stock Exchange. In order to maximize the value of the company for all stakeholders, Cellect has voluntarily filed for delisting from Tel Aviv Stock Exchange.

Near-term catalyst:

-- Definitive and complete results from a trial of ApoGraft process in healthy volunteers are expected before the end of this quarter (Q1, 2017). The company's ApoGraft process is designed to prevent Graft-versus-Host Disease (GvHD), a common complication associated with stem cell transplant.

6. Zosano Pharma Corp. (ZSAN)

Stock rallied for the second consecutive day, gaining 18.82% to close Tuesday's trading at $2.02.

News: No news

Recent event: On Feb.13, the company announced that its pivotal phase III efficacy study of M207 in migraine met endpoints.

In the pivotal phase III efficacy study, dubbed ZOTRIP, M207 achieved both co-primary endpoints of pain freedom and most bothersome symptom freedom at 2 hours.

M207 is a zolmitriptan-coated microneedle patch that is designed to rapidly deliver anti-migraine agent zolmitriptan during a migraine attack.

7. InspireMD Inc. (NSPR)

Gained 18.14% to close Tuesday's trading at $2.67.

News: No news

The company's CGuard Embolic Prevention System (EPS) is designed to prevent peri-procedural and late embolization. It is CE Marked, but not approved for sale in the U.S. by the FDA.

Anticipated events:

-- Commercial launch of CGuard EPS in Brazil in the first half of 2017. -- Commercial launch of CGuard EPS in India in the second half of 2017. -- File an IDE submission for CGuard EPS in the United States this year.

8. Cara Therapeutics Inc. (CARA)

Gained 14.95% to close Tuesday's trading at $15.53, after yesterday's loss of over 15%.

News: No news

Near-term catalyst: Top-line data from Part A of the company's phase 2/3 trial of I.V. CR845 in pruritus associated with chronic kidney disease are anticipated this quarter (Q1 2017).

9. Novan Inc. (NOVN)

Gained 12.44% to close Tuesday's trading at $4.79.

News: No news

Recent event: On January 27, 2017, the company reported top-line results from its two, replicate phase III pivotal clinical trials for SB204 in the treatment of acne vulgaris.

In one of those trials, dubbed NI-AC302, SB204 demonstrated statistical significance compared to vehicle on all three co-primary endpoints, but in another trial, named NI-AC301, the topical acne product candidate demonstrated statistical significance on only one of three co-primary endpoints. Following the results, the stock shed 74% of its value that day.

The company had its IPO on September 21, 2016, offering its shares at a price of $11.00 each.

LOSERS

1. Aviragen Therapeutics Inc. (AVIR)

Lost 37.22% to close Tuesday's trading at $0.68.

News: Aviragen's phase IIb study of Vapendavir in moderate to severe asthmatics with a rhinovirus (RV) infection failed to meet endpoints.

The phase IIb study of Vapendavir, dubbed SPIRITUS, did not demonstrate a statistically significant reduction in the asthma control questionnaire-6 (ACQ-6) at day 14, the primary endpoint.

2. Ohr Pharmaceutical Inc. (OHRP)

Lost 18.52% to close Tuesday's trading at $1.10.

News: Ohr has paused enrollment in its first phase III trial of its lead drug candidate Squalamine, a topical formulation, for the treatment of neovascular age-related macular degeneration (wet AMD).

The phase III program of Squalamine includes two double-masked, placebo-controlled, multicenter, international studies of Squalamine administered topically twice a day in patients with newly diagnosed wet AMD, in combination with Lucentis injections.

The enrollment pause is not related to any safety issue. The company believes that this approach will help to provide prospective efficacy data before year end 2017 to enable it to potentially confirm the visual acuity benefits observed in the patient population identified as the most likely to benefit from Squalamine combination therapy.

3. Catalyst Biosciences Inc. (CBIO)

Lost 17.58% to close Tuesday's trading at $7.83. A pullback after yesterday's gain of over 22%.

News: No news

Recent event: A 1-for-15 reverse stock split was implemented after the market close on Friday (Feb.10, 2017) and it began trading on a split-adjusted basis at the opening of trading on February 13, 2017.

The reverse stock split was effected in order is to enable Catalyst to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. Following the reverse split, the number of shares of Catalyst's common stock outstanding has decreased from approximately 13.0 million pre-split shares to approximately 868,000 post-split shares.